Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
dc.contributor.author | Kilickap, S. | |
dc.contributor.author | Demirci, U. | |
dc.contributor.author | Bugdayci, F. | |
dc.contributor.author | Tural, D. | |
dc.contributor.author | Korkmaz, T. | |
dc.contributor.author | Paydas, S. | |
dc.contributor.author | Yilmaz, C. | |
dc.contributor.author | Turna, H. | |
dc.contributor.author | Sezer, A. | |
dc.contributor.author | Cinkir, H. Yesil | |
dc.contributor.author | Okutur, K. | |
dc.contributor.author | Erman, M. | |
dc.contributor.author | Eralp, Y. | |
dc.contributor.author | Cabuk, D. | |
dc.contributor.author | Isikdogan, A. | |
dc.contributor.author | Demirkazik, A. | |
dc.contributor.author | Karaoglu, A. | |
dc.contributor.author | Yazilitas, D. | |
dc.contributor.author | Senler, F. Cay | |
dc.contributor.author | Yumuk, P. F. | |
dc.contributor.author | Coskun, H. | |
dc.contributor.author | Yildiz, I. | |
dc.contributor.author | Oztop, I. | |
dc.contributor.author | Beypinar, I. | |
dc.contributor.author | Aydin, K. | |
dc.contributor.author | Kaplan, M. | |
dc.contributor.author | Meydan, N. | |
dc.contributor.author | Olmez, O. F. | |
dc.contributor.author | Ozyilkan, O. | |
dc.contributor.author | Seber, S. | |
dc.contributor.author | Arslan, C. | |
dc.contributor.author | Sendur, M. A. | |
dc.contributor.author | Cicin, I. | |
dc.date.accessioned | 2023-02-21T12:42:25Z | |
dc.date.available | 2023-02-21T12:42:25Z | |
dc.date.issued | 2019-01-01 | |
dc.description.issue | 10 | |
dc.description.issue | S | |
dc.description.pages | OCT | |
dc.description.volume | 14 | |
dc.identifier.doi | 10.1016/j.jtho.2019.08.1166 | |
dc.identifier.uri | https://hdl.handle.net/11443/2813 | |
dc.identifier.uri | http://dx.doi.org/10.1016/j.jtho.2019.08.1166 | |
dc.identifier.wos | WOS:000492162203082 | |
dc.relation.ispartof | JOURNAL OF THORACIC ONCOLOGY | |
dc.title | Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
- Name:
- Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients Experience from anEarly Access Program in Turkey.pdf
- Size:
- 419.92 KB
- Format:
- Adobe Portable Document Format